On Wednesday, in the course of current trade, Shares of MagneGas Corporation (NASDAQ:MNGA), dropped -1.42%, and is now trading at $1.39.
MagneGas Corporation, declared that it successfully accomplished a MagneGas2® presentation to a second top ten utility company in the United States. Formal demonstration and testing has been planned for June. In February, MagneGas2® was accepted by one of the nation’s top 5 utilities as a replacement for acetylene because of its improved productivity and safety features.
Officials for the company viewed a MagneGas presentation and indicated an interest in MagneGas® productivity and safety features. A formal demonstration and testing is planned for June, during which time the utility company indicated they would invite other local utility companies in the area to attend. They specified that they were interested in using MagneGas® for repairs and demolition projects.
MagneGas Corporation, an alternative energy company, creates and produces hydrogen based alternative fuel through the gasification of carbon-rich liquids in the United States and internationally. The company produces and distributes gas bottled in cylinders to the metalworking market as an alternative to acetylene.
During an Afternoon trade, Shares of Bristol-Myers Squibb Company (NYSE:BMY), gained 1.20%, and is now trading at $69.09, hitting its highest level.
Bristol-Myers Squibb Company, declared that the U.S. Food and Drug Administration (FDA) has amended a formerly granted Breakthrough Therapy Designation for the investigational daclatasvir and sofosbuvir combination for use in hepatitis C (HCV) patients. The updated Designation reflects recently presented data on HCV genotype 1 patients with advanced cirrhosis (Child-Pugh Class B or C) and those who develop genotype 1 HCV recurrence post-liver transplant. Breakthrough Therapy Designation requires preliminary clinical evidence that demonstrates a drug may have substantial improvement on at least one clinically noteworthy endpoint over accessible therapy.
The designation is supported by data from ALLY-1, a Phase III clinical trial evaluating a 12-week regimen of daclatasvir and sofosbuvir once-daily with ribavirin for the treatment of patients with HCV with either advanced cirrhosis or post-liver transplant recurrence of HCV. Results from ALLY-1 were recently presented at The International Liver Congress™ 2015, this year’s annual meeting of the European Association for the Study of the Liver.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecules, and biologics in various therapeutic areas, counting virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; immunoscience; and cardiovascular.
Shares of Trimble Navigation Limited (NASDAQ:TRMB), during its Wednesday’s current trading session fell -0.53%, and is now trading at $24.29.
Trimble Navigation Limited, declared the availability of Trimble® GasOMS™ system, an integrated outage administration solution that enables natural gas utilities to model and simulate outage planning, streamline service restoration workflows, automate communications during service interruptions, and enhance Distribution Integrity Administration Plan (DIMP) reporting. By using Trimble GasOMS, natural gas utilities can reduce operational costs, keep customers better informed during outages, and support regulatory reporting requirements with compliance data that is traceable, verifiable and defensible.
The declaration was made at the American Gas Association Operations Conference & Biennial Exhibition.
Trimble Navigation Limited provides technology solutions to enhance the work processes of office and mobile field professionals worldwide. The company’s Engineering and Construction segment offers field and office software for route selection and design; systems to guide and control construction equipment; systems to monitor, track, and manage assets, equipment, and workers; software to share and communicate data; 3D conceptual design and modeling software.
Finally, Canadian Pacific Railway Limited (NYSE:CP), lost -0.25% Wednesday.
Canadian Pacific Railway Limited, declared that all resolutions placed in front of shareholders at its 2015 annual meeting (AGM) held in Calgary earlier recently, counting the election of all 13 nominees listed in the administration proxy circular dated March 17, 2015 as directors of CP, have been passed.
CP shareholders also approved the adoption of the Advance Notice By-Law to establish a framework for advance notice of nominations of directors by the shareholders of CP. The purpose of the Advance Notice By-Law is to ensure that an orderly nomination process is observed and that shareholders can make a well-informed voting decision about director nominees.
Additionally, shareholders approved a special resolution to authorize the holding of meetings of shareholders within Canada or the United States of America as the directors may from time to time determine, counting, but not limited to, Chicago, Illinois, Minneapolis, Minnesota, Saint Paul, Minnesota and New York, New York.
Canadian Pacific Railway Limited, through its auxiliaries, operates a transcontinental railway in Canada and the United States. The company provides logistics and supply chain expertise services. It transports bulk commodities, counting grain, coal, fertilizers, and sulphur; and intermodal traffic comprising retail goods in overseas containers that can be transported by train, ship, and truck, in addition to in domestic containers and trailers that can be moved by train and truck.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
